Register Now for Cello Health BioConsulting's Fireside Chat with EVP & Oncology Practice Lead Jeff Bockman and Scorpion Therapeutics' CEO Axel Hoos

October 19, 2021 // VIRTUAL
1:00-2:00PM EDT

Cello Health BioConsulting is a knowledge-based consultancy deeply rooted in science and the unique and ever-evolving challenges and opportunities facing the biopharma industry. Cello Health BioConsulting provides strategic advice for corporate growth and partnering strategies, disease area selection, indication prioritization, early market access strategy and early value profile development. Cello Health BioConsulting is known for “unconventional insight” – forward thinking, independent, objective and actionable strategic advice to realize value across all therapeutic areas and stages of development.

Precision Oncology 2.0: What Can It Deliver?

Therapies designed to target cancers with specific molecular signatures have led to a major paradigm shift in the oncology drug development and management of cancer patients. Profiling of the molecular changes across cancers has uncovered a diverse range of genetic alterations, including mutations, many of which are key drivers of cancer (such as oncogenes), the targeting of which offers the hope of crippling tumor cells at their most fundamental level. Advances beginning with targeting of HER2+ breast cancer by biologics like Herceptin (trastuzumab) and the inhibition of genetic aberrations like the bcr-abl translocation by Gleevec (imatinib) in CML, BRAF mutations in melanoma and ALK mutations in Non-Small Cell Lung Cancer (NSCLC) have heralded a whole variety of therapeutic breakthroughs with both large and small molecules.  Most recently there has been the first approval of an EGFR/HER2 Exon 20 insertion mutation targeting drug mobocertinib/Exkivity in NSCLC (Sept 15, 2021). Identification of these key genetic alterations has also enabled new clinical study designs and approvals of therapeutics agnostic of histology.

But it is time now to advance to the next level, to move us to Precision Oncology 2.0. Multiple advances over the last 20 years have led to a convergence of science AND technology that can be integrated for faster and smarter drug development. First, improving on the efficacy, for despite the many approved targeted agents, many small molecule kinase inhibitors of mutated cancer genes have been limited by the durability of remission, despite having often high initial response rates. Such relapses are driven by additional compensatory mutations or altered cell signaling pathways. Second, suboptimal therapeutic indices compromise tolerability, and hence compliance and outcomes.  Third, many promising targets are not classically druggable.  Finally, the role of immuno-oncology (IO) agents in the context of these genetic alterations is complex and in need of refined understanding.


Jeff Bockman, PH.D., EVP & Oncology Practice Lead, Cello Health BioConsulting

Jeff leads the Oncology practice at Cello Health BioConsulting, the firm’s largest practice area. He earned his PhD from Berkeley in Molecular Virology, working on prions, and completed a post-doc at The George Washington School of Medicine. His first stint in industry was at a start-up biotech working on oligonucleotide therapeutics for cancer and infectious diseases.

arrow FULL BIO

Axel Hoos, M.D., PH.D.,CEO, Scorpion Therapeutics

Dr. Axel Hoos is a distinguished physician-scientist, executive, entrepreneur and leader who became the CEO of Scorpion Therapeutics in August 2021. Prior to Scorpion, he served as Senior Vice President, R&D Governance Chair, and Therapeutic Area Head for oncology at GlaxoSmithKline Pharmaceuticals (GSK)

arrow FULL BIO


Cello Health BioConsulting
25-B Hanover Road, Suite 320
Florham Park, NJ 07932
T: + 1 973 292 5001 | F: +1 973 292 5002 | |

Let’s work together!

linkedin twitter